US EditionPublished • loading... • Updated
Sinorda and WuXi Partner on Bispecific Antibody Development and Manufacturing
Sinorda Biomedicine, a clinical stage biopharma firm located in Guiyang, Guizhou, China, agreed to collaborate with WuXi Biologics, a China-based CRDMO, on the development and manufacturing of SND006, a bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. Officials at Sinorda say the company will leverage WuXi Biologics’ experience and manufacturing capabilities in biologics developm…
1 Articles
1 Articles
Sinorda and WuXi Partner on Bispecific Antibody Development and Manufacturing
Sinorda Biomedicine, a clinical stage biopharma firm located in Guiyang, Guizhou, China, agreed to collaborate with WuXi Biologics, a China-based CRDMO, on the development and manufacturing of SND006, a bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. Officials at Sinorda say the company will leverage WuXi Biologics’ experience and manufacturing capabilities in biologics developm…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
